As a company dedicated to saving and improving lives, Merck recognizes that we have a special responsibility to help. In response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees and their families, ensuring that our supply of medicines and vaccines reaches our patients and customers, contributing our scientific expertise to the development of antiviral and vaccine approaches, and supporting health care providers and our communities. We thank the many health care providers and volunteers, including our own employees, who are doing so much to help affected patients and communities.
We know many of you have questions and we want to answer them as best as we can. To help you navigate your questions, we’re providing the list of FAQs below.
As a company dedicated to saving and improving lives for more than 100 years, we have a special responsibility to help in the fight against COVID-19. Merck has been fully committed to developing an effective response to the COVID-19 pandemic since it was first recognized, and we know that success will require global collaboration among countries and companies and more.
In May we announced two COVID-19 vaccine development efforts – a collaboration with IAVI and plans to acquire Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases, including COVID-19. We also announced a research collaboration with Ridgeback Biotherapeutics to develop a novel oral antiviral candidate for the treatment of COVID-19. In addition to the collaborations with IAVI and Ridgeback Bio, and the acquisition of Themis, we are participating in a research collaboration with the Institute for Systems Biology to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines, as well as the NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV consortium). ACTIV is a partnership that aims to develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials and regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
We believe a range of medicines and vaccines will be needed to end the pandemic, and we will continue to pursue multiple pathways and collaborate with others.
As has been the case with many diseases, we are optimistic that our industry’s efforts will create new tools and that the unprecedented collaboration we are seeing today will accelerate these efforts. This pandemic underscores the need for our company and our industry to continue to invest in research for the greatest health threats.
Driven by our steadfast commitment to patients, we are taking a number of new steps to support patients in the United States who may have lost their jobs and insurance coverage. We will continue to ensure access to Merck medicines at no cost for eligible U.S. patients through its Merck Patient Assistance Program, created 60 years ago based on the company’s belief that no one should go without the medicines or vaccines they need. In response to the COVID-19 pandemic, the Merck Patient Assistance Program is making a number of changes to help patients who have lost their job or cannot get into their doctor’s office during this crisis, including assessing patients’ real-time financial situations, providing assistance with expiring enrollments, and offering new options to collect signatures on enrollment forms.
To learn more about resources Merck has available for patients who need help during the COVID-19 pandemic and beyond, call 1-800-672-6372 or visit our information page on Merck.com.
While the situation remains fluid, there are not any current impacts from COVID-19 on the production and supply of our medicines and vaccines for the U.S. However, we are working to assess an increase in demand for an anti-parasitic. As communities around our manufacturing facilities are impacted by various social distancing measures implemented by authorities, we will assess the impact of reduced staffing levels on our supply chains.
Driven by our steadfast commitment to patients, we are making every effort to ensure that patients in affected areas who are enrolled in clinical trials are able to continue their treatment and receive appropriate care and monitoring. Conditions are fluid and evolving, but as local conditions allow, we are enrolling patients in ongoing studies and we are starting new studies.
We have taken extensive steps to ensure that any sites that are currently open, including our plants and labs around the world, are as safe as possible for our colleagues and to provide additional support to our colleagues who are working on our sites. Our other colleagues are working remotely – and, together, we are all focused on advancing Merck’s mission to save and improve lives. We have paused in-person interactions with health care providers in many places, including the U.S. We are also asking all employees to follow global health recommendations on handwashing and social distancing. And, if any of our employees is experiencing symptoms of fever, shortness of breath, we’ve asked them to stay home - this applies during this outbreak - and is a good practice at any time.
We are committed to supporting our health care providers and our communities. Where possible, our employees around the world are helping, including contributing volunteer services and donations to support both local and global responses. Read more about how we are supporting communities.
If you have questions on a Merck medication, please contact our National Service Center at firstname.lastname@example.org or call us at 1-800-672-6372.
Listen as Merck’s Dr. Julie L. Gerberding and BIO’s Phyllis Arthur discuss the outbreak and its public health impact